RET and thyroid gland papillary carcinoma: Selpercatinib (29) is a rearranged during transfection (RET) receptor tyrosine kinase inhibitor approved for cancers harboring RET mutations (metastatic RET fusion-positive NSCLC, advanced/metastatic RET-altered medullary thyroid cancer and papillary thyroid carcinoma).